The prevalence of sickling abnormality in Oman: A review of relevant publications

The prevalence of sickling abnormality in Oman: A review of relevant publications



Sickle cell disease, Hb SS, genotype, phenotype, severity, HbF, Hb Sβ-thalassemia, Oman


Sickle cell disease (SCD), caused by a mutation in the β-globin gene HBB, is widely distributed in malaria endemic regions.  The prevalence of sickle cell trait and disease reaches up to 4.8–6% and 0.2% respectively, which is the highest among the Arab Gulf states.  Omani population represents a variability of HbS genotype combinations with other Hb genotypes modify the clinical severity of the disease. The most prevalent sickling abnormality in Oman is Hb S/S (SCA) followed by Hb S/β-thalassemia. Omani children with SCD with high Hb F level had less severe disease. More than two-thirds of SCD cases were running a mild course of the disease due to the high prevalence of  a-thalassemia trait. The severity index has been correlated with the early age of presentation, the absence of  a-thalassemia trait and the lower level of HbF as well as to the existence of different β-globin gene haplotypes.  S/ β0 presented with the same clinical severity of S/S while those with S/ β+ had some splenic function into adulthood and were more prone to splenic sequestration. The unique existence of HbS-Oman (a severe variant of sickle hemoglobinopathy) markedly increased the severity of the disease. Compound heterozygotes HbS-Oman resulted in very severe clinical manifestations with transfusion-dependency and hypersplenism early in life. This paper summarizes and reviews βs gene haplotypes in patients with sickle cell anemia (SCA) in Oman. (


Daar S, Hussein H, Gravell D, Nagel R, Krishnamoorthy R. Genetic epidemiology of HbS in Oman: multicentric origin for the betaS gene. Am J Hematol 2000; 64:39-46.

Kwiatkowski DP. How malaria has affected the human genome and what human genetics can teach us about malaria. Am J Hum Genet 2005; 77:171-92.

Wali Y, AlBalushi H, Nazir HF. Sickle cell disease in Oman and HBS Oman: a brief review. Hematol Transfus Int J 2017; 4:142-3.

Ha J, Martinson R, Iwamoto SK, Nishi A. Hemoglobin E, malaria and natural selection. Evol Med Public Health 2019; 2019:232-41.

Rajab AG, Patton MA, Modell B. Study of hemoglobinopathies in Oman through a national register. Saudi Med J 2000; 21:1168-72.

Al-Riyami A, Ebrahim GJ. Genetic Blood Disorders Survey in the Sultanate of Oman. J Trop Pediatr 2003;49 Suppl 1:1-20.

Alkindi S, Al Zadjali S, Al Madhani A, et al. Forecasting hemoglobinopathy burden through neonatal screening in Omani neonates. Hemoglobin 2010; 34:135-44.

Al Zeedi MASA, Al Abri ZG. Attitudes and impact among people with abnormal premarital screening test results in Muscat governorate's primary healthcare centers in 2018. J Community Genet 2021; 12:163-9.

Al-Riyami AA, Suleiman AJ, Afifi M, Al-Lamki ZM, Daar S.A community-based study of common hereditary blood disorders in Oman. East Mediterr Health J 2001; 7:1004-11.

Alkindi S, Al Zadjali S, Al Madhani A, et al. Forecasting hemoglobinopathy burden through neonatal screening in Omani neonates. Hemoglobin 2010; 34:135-44.

Hassan, S., Muslahi, M. , Riyami, M., et al. (2015). Haplotypes, Sub-Haplotypes and Geographical Distribution in Omani Patients with Sickle Cell Disease. Thalassemia Reports 2015; 5:

Hassan SM, Hamza N, Jaffer Al-Lawatiya F, et al. Extended molecular spectrum of β-and α-thalassemia in Oman. Hemoglobin 2010; 34:127-34.

Al-Lamki Z, Wali YA, Wasifuddin MS, et al. Natural History of Sickle hemoglobinopathy in Omani Children. Int J Paediatr Haematol Oncol 2000;7:101–7.

Saraf SL, Molokie RE, Nouraie M, et al. Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatr Respir Rev 2014;15:4-12.

Benites BD, Bastos SO, Baldanzi G, et al. Sickle cell/β-thalassemia: Comparison of Sβ0 and Sβ+ Brazilian patients followed at a single institution. Hematology 2016;21:623-9.

Wali YA, Al-Lamki Z, Hussein SS, et al. Splenic function in omani children with sickle cell disease: correlation with severity index, hemoglobin phenotype, iron status, and -thalassemia trait. Pediatr Hematol Oncol 2002; 19:491–500.

Adekile AD, Tuli M, Haider MZ, Al-Zaabi K, Mohannadi S, Owunwanne A. Influence of alpha-thalassemia trait on spleen function in sickle cell anemia patients with high HbF. Am J Hematol 1996; 53:1-5.

Langdown JV, Williamson D, Knight CB, Rubenstein D, Carrell RW. A new doubly substituted sickling haemoglobin: HbS-Oman. Br J Haematol 1989; 71:443–4.

Al-Balushi HWM, Wali Y, Al Awadi M, et al. The super sickling haemoglobin HbS-Oman: a study of red cell sickling, K+ permeability and associations with disease severity in patients heterozygous for HbA and HbS-Oman (HbA/S-Oman genotype). Br J Haematol 2017; 179:256-65.

Suresh V, Asila NS, Nafisa MZ, Laitha MN, Susamma M. Haemoglobin S Oman trait- A sickling variant. Oman Med J 1999; 16:23–4.

Al Jahdhamy R, Makki H, Farrell G, Al Azzawi S. A case of compound heterozygosity for Hb S and Hb S Oman. Br J Haematol 2002; 116:504.

Knox-Macaulay HH, Ahmed MM, Gravell D, Al-Kindi S, Ganesh A. Sickle cell-haemoglobin E (HbSE) compound heterozygosity: a clinical and haematological study. Int J Lab Hematol 2007; 29:292-301.

Thalagahage KH, Jayaweera JAAS, Kumbukgolla W, et al. HbS/D-Punjab Disease: Report of 3 Cases from Sri Lanka. Indian J Hematol Blood Transfus 2018; 34:350-2.



31-08-2022 — Updated on 18-10-2022





How to Cite

Al-Mashaikhi N, Al-Rawas A, Wali Y, Soliman A, Khater D. The prevalence of sickling abnormality in Oman: A review of relevant publications. Acta Biomed [Internet]. 2022 Oct. 18 [cited 2024 Jul. 15];93(4):e2022289. Available from: